BBNX · XBRL financial data

Beta Bionics financial statements, every quarter

The same tables from 9 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (BBNX's year ends in late December)

In thousands of dollars	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Revenue from contracts with customers	20,440*	17,639	23,238	27,253	32,121*	27,626	32,013	35,505
Cost of goods and services sold	8,751*	8,668	10,735	12,134	13,177*	11,189	13,111	15,174
Gross profit	11,689*	8,971	12,503	15,119	18,944*	16,437	18,902	20,331
Research and development	9,214*	7,590	8,873	8,195	10,131*	10,356	10,240	11,975
General and administrative	4,708*	6,621	7,879	7,922	8,603*	9,617	9,600	9,841
Total operating expenses	24,726*	27,613	32,375	32,162	35,068*	40,708	44,480	46,940
Operating income (loss)	(13,037)*	(18,642)	(19,872)	(17,043)	(16,124)*	(24,271)	(25,578)	(26,609)
Interest income	951*	2,436	3,005	2,833	2,658*	2,376	2,177	2,258
Other income (expense)	0*	0	(2)	1	0*	—	(2)	(2)
Income tax expense (benefit)	year only	—	—	—	year only	—	—	—
Net income (loss)	(18,108)*	(28,656)	(16,869)	(14,209)	(13,466)*	(21,895)	(23,403)	(24,353)
Earnings per share, basic USD per share	(2.72)*	(0.93)	(0.39)	(0.33)	—	(0.49)	(0.53)	(0.52)
Earnings per share, diluted USD per share	(2.72)*	(0.93)	(0.39)	(0.33)	—	(0.49)	(0.53)	(0.52)
Weighted average shares, basic thousands of shares	6,666*	30,715	43,391	43,634	44,195*	44,436	44,545	46,542
Weighted average shares, diluted thousands of shares	6,666*	30,715	43,391	43,634	44,195*	44,436	44,545	46,542

Fiscal quarters (BBNX's year ends in late December)

In thousands of dollars	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Cash and cash equivalents	30,432	42,454	35,075	38,485	31,576	30,206	44,318	81,551
Short-term investments	73,143	189,019	214,645	190,202	187,549	169,314	136,171	158,653
Accounts receivable	11,996	9,060	11,395	11,539	17,118	15,750	18,053	20,667
Inventory	13,320	15,730	17,323	20,373	21,722	23,727	23,918	22,971
Prepaid and other current assets	4,032	5,652	7,637	9,427	9,840	8,889	8,474	9,004
Total current assets	132,923	261,915	286,075	270,026	267,905	247,986	231,034	292,946
Property and equipment, net	4,776	5,515	6,465	7,385	8,600	10,160	10,748	11,764
Right-of-use asset	6,645	6,344	6,038	7,024	6,627	6,225	5,816	5,401
Total assets	149,645	338,024	329,971	330,046	328,743	304,417	292,387	443,759
Accounts payable	2,852	3,454	3,424	4,461	4,998	2,318	5,351	4,682
Total current liabilities	21,148	16,492	19,489	25,388	30,924	23,191	26,017	32,836
Lease liability, non-current	5,726	5,450	5,168	5,707	5,365	5,073	4,921	4,649
Total liabilities	73,632	24,272	28,338	35,286	41,133	33,172	36,021	42,376
Accumulated deficit	(296,737)	(325,393)	(342,262)	(356,471)	(369,937)	(391,832)	(415,235)	(439,588)
Total stockholders' equity	(245,360)	313,752	301,633	294,760	287,610	271,245	256,366	401,383
Total liabilities and equity	149,645	338,024	329,971	330,046	328,743	304,417	292,387	443,759
Common shares outstanding (cover page) thousands of shares	43,349	43,356	43,470	44,025	44,382	44,562	44,990	54,367

Fiscal quarters (BBNX's year ends in late December)

In thousands of dollars	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026	Q3 FY26Sep 30, 2026
Net income (loss)	(18,108)*	(28,656)	(16,869)	(14,209)	(13,466)*	(21,895)	(23,403)	(24,353)
Stock-based compensation	1,552*	2,804	4,799*	4,478*	4,303*	5,406	7,016*	6,715*
Net cash from operating activities	(14,279)*	(19,975)	(13,594)*	(8,729)*	(8,627)*	(23,832)	(14,622)*	(12,287)*
Purchases of property and equipment	561*	333	1,779*	1,282*	1,903*	1,377	1,039*	2,275*
Net cash from investing activities	(29,662)*	(179,122)	6,173*	9,486*	658*	21,839	26,933*	(114,080)*
Proceeds from issuing common stock	—	195,430	0*	0*	(904)*	—	—	—
Net cash from financing activities	56,892*	211,119	42*	2,653*	1,060*	623	1,801*	163,600*
Net change in cash	12,951*	12,022	(7,379)*	3,410*	(6,909)*	(1,370)	14,112*	37,233*

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Beta Bionics	81,551	35,505	(12,287)*	54.4M	13.0 quarters	Q3 FY26 10-QSep 30, 2026
Kestra Medical Technologies	68,558	30,971	(32,295)	59.6M	4.9 quarters	Q1 FY26 10-QJul 31, 2026
Cadre Holdings	53,984	207,126	22,131*	42.8M	—	Q2 FY26 10-QJun 30, 2026
Avanos Medical	65,600	182,200	(12,300)	46.8M	5.3 quarters	Q1 FY26 10-QMar 31, 2026
Mimedx Group	120,791	62,283	3,919*	145.9M	—	Q3 FY26 10-QSep 30, 2026
Embecta	214,700	271,700	41,800*	56.7M	—	Q3 FY26 10-QJun 30, 2026
SI-BONE	33,128	56,010	777*	44.8M	—	Q2 FY26 10-QJun 30, 2026
Iradimed	63,288	24,203	6,997*	12.8M	—	Q3 FY26 10-QSep 30, 2026
Biolife Solutions	23,997	not reported	6,348*	48.9M	—	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.